Loading clinical trials...
Loading clinical trials...
Phospholipid Endoplasmic Reticulum Stress in Nonalcoholic Fatty Liver Disease
The investigators overall hypothesis is that exacerbation of endoplasmic reticulum (ER) stress in the liver is associated with significant alterations in phosphatidylcholines that drive the NASH phenotype in obese humans. The investigators plan to examine this hypothesis in a well-characterized cohort of obese subjects that are scheduled for bariatric surgery. Methyl-D9-choline chloride will be infused before and after a 2-week high fructose or glucose feeding to determine the biosynthesis and kinetics of secretory lipoprotein phospholipids. It is proposed that phospholipid metabolism play an important role in the pathogenesis or etiology of fatty liver in non-alcoholic conditions through mechanisms that invoke ER and oxidative stress responses.
Age
30 - 60 years
Sex
FEMALE
Healthy Volunteers
No
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Start Date
October 1, 2013
Primary Completion Date
October 1, 2017
Completion Date
April 1, 2018
Last Updated
October 23, 2013
methyl-D9-choline
DRUG
Lead Sponsor
Vanderbilt University
NCT07472881
NCT01143454
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions